Halozyme Therapeutics Inc. to Post FY2016 Earnings of ($0.83) Per Share, Jefferies Group Forecasts (HALO)
Halozyme Therapeutics Inc. (NASDAQ:HALO) – Equities research analysts at Jefferies Group raised their FY2016 earnings estimates for shares of Halozyme Therapeutics in a research report issued on Monday. Jefferies Group analyst E. Yang now forecasts that the firm will earn ($0.83) per share for the year, up from their prior forecast of ($0.90). Jefferies Group currently has a “Sell” rating and a $6.75 price objective on the stock. Jefferies Group also issued estimates for Halozyme Therapeutics’ Q4 2016 earnings at ($0.24) EPS, Q2 2017 earnings at ($0.25) EPS, Q3 2017 earnings at ($0.26) EPS, Q4 2017 earnings at ($0.26) EPS, FY2017 earnings at ($1.01) EPS, FY2018 earnings at ($0.93) EPS, FY2019 earnings at ($0.47) EPS and FY2020 earnings at ($0.23) EPS.
A number of other research analysts also recently commented on HALO. Deutsche Bank AG began coverage on Halozyme Therapeutics in a report on Thursday, November 3rd. They issued a “buy” rating and a $12.00 price target for the company. Wells Fargo & Co. reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, September 8th. Finally, Piper Jaffray Cos. increased their price target on Halozyme Therapeutics from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Friday, September 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Halozyme Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $15.54.
Halozyme Therapeutics (NASDAQ:HALO) opened at 12.58 on Thursday. Halozyme Therapeutics has a 12-month low of $6.96 and a 12-month high of $18.39. The firm’s market cap is $1.61 billion. The stock has a 50 day moving average price of $10.51 and a 200-day moving average price of $9.92.
Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.04. The business had revenue of $31.90 million for the quarter, compared to analyst estimates of $34.43 million. Halozyme Therapeutics had a negative return on equity of 405.28% and a negative net margin of 44.60%. The company’s revenue for the quarter was up 53.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.19) earnings per share.
Hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in shares of Halozyme Therapeutics by 359.0% in the second quarter. Bank of New York Mellon Corp now owns 2,279,701 shares of the biopharmaceutical company’s stock worth $19,674,000 after buying an additional 1,783,067 shares during the last quarter. Senzar Asset Management LLC bought a new stake in shares of Halozyme Therapeutics during the second quarter worth $6,781,000. FMR LLC boosted its stake in shares of Halozyme Therapeutics by 12.5% in the second quarter. FMR LLC now owns 6,691,247 shares of the biopharmaceutical company’s stock worth $57,745,000 after buying an additional 745,567 shares during the last quarter. Snyder Capital Management L P boosted its stake in shares of Halozyme Therapeutics by 35.0% in the second quarter. Snyder Capital Management L P now owns 2,267,787 shares of the biopharmaceutical company’s stock worth $19,571,000 after buying an additional 587,618 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Halozyme Therapeutics by 15.9% in the first quarter. State Street Corp now owns 3,472,472 shares of the biopharmaceutical company’s stock worth $32,884,000 after buying an additional 475,807 shares during the last quarter. Institutional investors and hedge funds own 80.34% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.